Pay in 4 interest-free payments of $7.14 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
FIGURE 4 3.4 H 2 suppressed pyroptosis in the liver of mice fed with a MCD diet In human and murine models of MASH, increased hepatocyte death, such as apoptosis and pyroptosis, is a critical mechanism contributing to inflammation and fibrogenesis (Hatting et al., 2013
Targeting mitochondria-inflammation circuit by beta-hydroxybutyrate mitigates HFpEF
TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
50 mcg / 1,000 = 0.05 mL = 5 units
Supports Normal Mood *
Each 10 mg vial is produced under ISO-certified conditions, verified 99% purity by HPLC, screened for endotoxin ( 98% integrity
US$ 21.92
US$ 29.96
US$ 29.73
US$ 23.96
US$ 28.08
US$ 23.80
US$ 29.95
US$ 28.81
